Please login to the form below

Not currently logged in
Email:
Password:

veno-occlusive disease

This page shows the latest veno-occlusive disease news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Pfizer's antibody drug for leukaemia

NICE rejects Pfizer's antibody drug for leukaemia

After the publication of the INO-VATE data oncologists welcomed having an alternative that is generally easier to tolerate than chemo, although Besponsa has been linked to veno-occlusive disease (VOD)

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... The US regulator has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    The Italy-based pharma company had applied for European approval of defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation therapy,

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    3, 080. Cosmo Technologies/ Salix Pharmaceuticals. Merger (tax inversion)    . Portfolio of treatments for gastrointestinal disease and disorders. ... 360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....